Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-018810
Filing Date
2025-02-12
Accepted
2025-02-12 16:00:20
Documents
68
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q enta-20241231.htm   iXBRL 10-Q 1629624
2 EX-10.1 enta-ex10_1.htm EX-10.1 165672
3 EX-10.2 enta-ex10_2.htm EX-10.2 135069
4 EX-31.1 enta-ex31_1.htm EX-31.1 11966
5 EX-31.2 enta-ex31_2.htm EX-31.2 11916
6 EX-32.1 enta-ex32_1.htm EX-32.1 12231
7 GRAPHIC img216988758_0.jpg GRAPHIC 1452180
  Complete submission text file 0000950170-25-018810.txt   10623758

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT enta-20241231.xsd EX-101.SCH 946773
71 EXTRACTED XBRL INSTANCE DOCUMENT enta-20241231_htm.xml XML 1315674
Mailing Address 4 KINGSBURY AVENUE WATERTOWN MA 02472
Business Address 4 KINGSBURY AVENUE WATERTOWN MA 02472 617 607 0800
ENANTA PHARMACEUTICALS INC (Filer) CIK: 0001177648 (see all company filings)

EIN.: 043205099 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-35839 | Film No.: 25614664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)